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Review Article

Trans-arterial embolisation therapies for unresectable intrahepatic
cholangiocarcinoma: a systematic review
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Background: Unresectable intrahepatic cholangiocarcinoma (ICC) portends a poor prognosis despite
standard systemic treatments which confer minimal survival benefits and significant adverse effects. This
study aimed to assess clinical outcomes, complications and prognostic factors of TAE therapies using
chemotherapeutic agents or radiation.
Methods: A literature search and article acquisition was conducted on PubMed (MEDLINE), OVID
(MEDLINE) and EBSCOhost (EMBASE). Original articles published after January 2000 on trans-arterial
therapies for unresectable ICC were selected using strict eligibility criteria. Radiological response, overall
survival, progression-free survival, safety profile, and prognostic factors for overall survival were assessed.
Quality appraisal and data tabulation were performed using pre-determined forms. Results were synthesized
by narrative review and quantitative analysis.
Results: Twenty articles were included (n=929 patients). Thirty three percent of patients presented with
extrahepatic metastases. After treatment, the average rate of complete and partial radiological response was
10% and 22.2%, respectively. Overall median survival time was 12.4 months with a median 30-day mortality
and 1-year survival rate of 0.6% and 53%, respectively. Acute treatment toxicity (within 30 days) was
reported in 34.9% of patients, of which 64.3% were mild to moderate in severity. The most common clinical
toxicities were abdominal pain, nausea and vomiting, and fatigue. Multiplicity, localization and vascularity of
the tumor may predict worse overall survival.
Conclusions: Trans-arterial therapies are safe and effective treatment options which should be considered
routinely for unresectable ICC. Consistent and standardized methodology and data collection is required to
facilitate a meta-analysis. Randomized controlled trials will be valuable in the future.
Keywords: Intrahepatic cholangiocarcinoma (ICC); unresectable; embolization; survival
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Introduction
Intrahepatic cholangiocarcinoma (ICC) is a devastating
malignancy of the biliary tree which is notoriously difficult
to diagnose (1). Survival remains at less than 12 months
after diagnosis due to clinical latency, lack of effective nonsurgical therapies and aggressive tumors (1-4). Surgical
resection is the only chance of cure, but in up to 70% of
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cases ICC is unresectable (5-8). Systemic chemotherapy and
radiotherapy as primary, adjuvant or palliative treatments
have poor response rates and are limited by systemic
toxicities (9-14).
Since 1980, TAE has become available for targeted
treatment of both primary and secondary hepatic
malignancies (15). The common modalities for TAE are
bland embolization, trans-arterial chemoembolization

www.thejgo.org

J Gastrointest Oncol 2015;6(5):570-588

Journal of Gastrointestinal Oncology Vol 6, No 5 October 2015

(TACE) or chemoinfusion (TACI), and selective internal
radiation therapy (SIRT). These are performed via the
hepatic artery and allow selective delivery of anti-tumor
agents or radioactive microspheres. This targeted approach
minimizes systemic toxicity or exposure of healthy tissue to
radiation.
TACE and TACI have shown to improve median
survival by 2-7 months compared to systemic therapies (16).
Several observational studies on SIRT have also reported
similar benefits on overall survival and tumor response rates
of up to 86% (17-19). In the context of inoperability and
increasing evidence of survival benefit conferred by transarterial approach, such therapies have become important
and widely used treatment options. However, systematic
evaluation of data for each treatment modality remains
limited.
This study reviews the effect of trans-arterial
emoblisation therapies for unresectable ICC. Primary
outcomes were response and survival outcomes. Secondary
outcomes were treatment complications and prognostic
factors for overall survival.
Methods
The structure of this systematic review followed the
PRISMA guidelines (20).
Definition of treatment modalities
TACE delivers high doses of chemotherapy directly to the
cancer cells via the hepatic artery. Additionally, embolic
agents are injected to reduce arterial inflow and increase
bioavailability of the drugs (21). Bland embolization is
another form of TACE that uses particles and/or embolic
agents to block blood flow to the tumor without the use
of chemotherapeutic agents. Another alternative includes
the use of drug-eluting beads embedded with irinotecan
(DEBTACE).
TACI is a catheter-based therapy using an arterial port
in the hepatic artery. Its delivery of chemotherapeutic drugs
is similar to TACE, but embolization is not used in TACE.
TACI maximizes targeted drug delivery by selective vessel
catheterization (5).
SIRT delivers internal radiation selectively to the tumor
bed. Yttrium-90 (Y90) is impregnated in glass or resinbased microspheres (5). The type, size and number of
microspheres per treatment varies (22).
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Eligibility criteria
Studies considered for review had the following predetermined inclusion criteria: (I) adult patients with
primary ICC; (II) unresectable, chemorefractory or failed
previous surgical resection; (III) TAE as the treatment
modality; and (IV) clinical outcomes and complications
assessed and reported. Resectibility is assessed using
patient and disease factors including comorbidities, fitness
for surgery and tumor location and size (23). A tumor is
deemed unresectable if clear margins cannot be achieved by
resection and there are evidence of metastases (24,25).
These studies were restricted according to the following
report characteristics: (I) publication date after January
2000; (II) English language; and (III) original research. The
search period was restricted to be more representative of
modern post-operative outcomes.
Information sources and search strategy
On December 2013, a literature search was conducted
using MeSH keyword search on PubMed (MEDLINE)
for all studies which matched the eligibility criteria
above (Figure 1). An additional manual search of OVID
(MEDLINE) and EBSCOhost (EMBASE) as well as
bibliographies of each included study was conducted to
identify studies not covered by the initial MeSH keyword
search. All identified articles were retrieved from the
aforementioned databases.
Study selection
Following the search, two reviewers independently
performed screening of titles and abstracts after MeSH
keyword and manual searches. Studies were excluded if
they did not meet eligibility criteria. Consensus for studies
included for review was achieved by discussion between
reviewers based on the pre-determined eligibility criteria.
Studies were classified into levels of evidence using the
National Health and Medical Research Council evidence
hierarchy (42).
Data items and extraction
All data items for assessment of study quality (Table 1) and
study results (Table 2) were pre-determined. Data extraction
was then performed by two independent reviewers using
a standardised protocol. Data extracted include the
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Risk of bias

Search algorithm
31/12/2013
“cholangiocarcinoma” [MeSH Terms]
AND “embolization, therapeutic”
[MeSH Terms] AND “unresectable”
[Text word] AND English [Language]
AND (“2000” [PDAT] “3000” [PDAT]
30 articles identified

The risk of bias in individual studies was assessed by a
qualitative analysis based on study quality and data tabulated
in Table 1.

Did not meet eligibility
criteria# 15 articles excluded

15 articles selected (17,19,23,26-37)

Plus manual search EMBASE, MEDLINE,
EBSCO databases and bibliographies of
all included studies 5 articles (18,38-41)

20 articles included (17-19,23,26-41)
Being appropriate for this review due to relevancy
to this topic and scientific accuracy of the
reported results

Figure 1 Search algorithm (17-19,23,26-41). # , eligibility
criteria outlined in methods section: (I) adult patients with
primary intrahepatic cholangiocarcinoma; (II) unresectable,
chemorefractory or failed previous surgical resection; (III) patients
received transarterial chemoembolization, chemoinfusion, and/
or radioembolization; (IV) assessment of clinical outcomes and
complications; (V) original research.

methodology, quality appraisal, patient characteristics,
treatment toxicity, radiological response, overall survival,
progression-free survival and prognostic factors. Overall
survival and progression-free survival were determined from
the time of TAE.
Synthesis of results
Data was synthesized by qualitative and quantitative
review based on the outcomes criteria and data extracted
in tables as outlined above. Statistical data are presented
as percentages or median (range). A meta-analysis was not
performed due to the following reasons: (I) heterogeneous
data prevented complete meta-analysis; some studies had
no reference population and others compared trans-arterial
therapy with surgery or systemic chemotherapy; (II) statistical
limitations due to missing data or inconsistencies in data
presentation and (III) methodological inconsistencies such
as varied follow-up time points for survival rates.
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Results
Study selection
After careful systematic selection, 20 studies were selected
for review (17-19,23,26-41). Full details of the search
algorithm are outlined in Figure 1.
Study characteristics and risk of bias within studies (Table 1)
The sample size ranged between 9 to 198. Only four studies
included greater than 50 patients (30-32,38). The number
of patients in most studies is low and this is a significant
source of bias.
Seven studies used radioembolization (1719,26,27,38,39). Hyder et al. compared TACE, DEBTACE
and traditional SIRT (38). TACI was assessed in two
studies (36,41). One study compared TACE with systemic
chemotherapy (29) and nine studies assessed TACE with no
comparators (23,28,30-33,35,37,40).
Heterogeneous patient demographics, tumor type and
pathology, and treatment combinations in included studies
resulted in a wide range of results derived from each
article (Tables 1,2). This discrepancy reflects the lack of
standardized protocol for trans-arterial therapies to facilitate
consistent patient selection and treatment regimens. These
therapies are relatively new, and although their efficacy has
been reported in multiple studies, a summary of evidence is
required.
Study design limited the strength of evidence of included
articles. Twelve studies were retrospective (19,26,2830,32,33,35-38,41) and no randomized controlled trial
was present in this review. Both are potential sources of
bias. The reasons for the lack of randomized studies may
be multifactorial. In the context of known survival benefit
conferred by trans-arterial therapies, it may be unethical to
deny patients trans-arterial therapies.
All studies had level of evidence II and III. The results of
studies were similar between lower (19,26,28-30,32,33,3538,41) and higher level (17,18,23,27,31,34,39,40) evidence
articles which demonstrates good consistency of results
across studies.
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Ibrahim (18), 2008

Kim (36), 2008

Shitara (41), 2008

Poggi (33), 2009
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P

P

Haug (27), 2011

Kiefer (31), 2011

P

Schiffman (40),

Table 1 (continued)

Hoffman (19), 2012

2011

R

R

a

Park (32), 2011

a

P

Saxena (17), 2010

a

a

P

design

Study

Burger (23), 2005

Author, year

Table 1 Quality appraisal

33

24

72

62

26

25

9

20

49

24

42

11

15

17

Patients

SIRT

DEBTACE

TACE

TACE

SIRT

SIRT

TACE

microspheres-

eluting

Oxaliplatin

TACI

TACE, TACI

microspheres

Glass

TACE

DEBTACE

TACE +

TACE

TACE

Treatment

13.5

13.6

NR

NR

NR

Yes

Yes

Yes

Yes

Yes

Yes

Yes

20

8.1

Yes

Yes

Yes

Yes

Yes

Yes

Yes

NR

8

17.7

NR

NR

3

16

criteria

27

80

NR

18

17

18

0

0

NR

29

NR

NR

4

35

12

29

NR

7

8

10

0

0

NR

NR

NR

NR

1

0

CTx Resection

duration inclusion
(months)

Previous
treatments (%)

Follow-up Explicit

No

No

No

No

No

Yes (28%)

Yes

No

33%)

radiation

No (adjuvant

No

No

No

No

No

CTx

Concomitant

None

None

Supportive treatment

None

None

No

CTx

None

TACE; TACI; TACE + TACI

None

cisplatin followed by oxaliplatin

gemcitabine + cisplatine; gemcitabine +

gemcitabine followed by oxaliplatin;

gemcitabine followed by cisplatin;

TACE combinations: gemcitabine only;

CTx

None

None

Comparison groups

Level of

III

II

III

II

II

II

III

III

III

II

III

II

III

II

evidence
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19
32

R

P

R

Mouli (26), 2013

Rafi (39), 2013

Scheuermann (28),

Yes

27-100

35

NA

19

16

55

NR

0

2

5

10-40

11.6

NA

NA

5

23

NR

7

0

1

CTx Resection

None

None

Yttrium-90

DEBTACE; bland embolization;

All IAT: TACE;

mitomycin-C + gemcitabine +cisplatin

mitomycin-C + gemcitabine;

All TACE: mitomycin-C; gemcitabine;

TACE + DEBTACE; TACE; ChT

Comparison groups

Adjuvant CTx Resection; CTx/supportive

No

No

(15%)

30 patients

No

No

No

No

CTx

Concomitant

Level of

III

II

III

III

III

III

evidence

prospective; R, retrospective; TACI, trans-arterial chemoinfusion; SIRT, selective internal radiation therapy.

a

, SIRT. CTx, systemic chemotherapy; TACE, trans-arterial chemoembolization; DEBTACE, drug eluting beads TACE; NA, not applicable; NR, not reported; P,

1.8-29

Yes

10

Yes

No

Yes

15

29

Range

doxorubicin

mitomycin C,

Lipiodol and

SIRT

SIRT

NR

NR

Yes

13

13.5

46

SIRT

TACE

oxaliplatin)

Yes

Yes

1.8

12

criteria

duration inclusion
(months)

Previous
treatments (%)

Follow-up Explicit

Median

2013

a

a

198

R

Hyder (38), 2013

a

115

ChT

31
(gemcitabine &

TACE

DEBTACE

TACE +

Treatment

10

26

Patients

R

R

design

Study

Vogl (30), 2012

2012

Kuhlmann (29),

Author, year
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Table 2 (continued)

Park (32), 2011

Kiefer (31), 2011

a

Haug (27), 2011

a

Saxena (17), 2010

Poggi (33), 2009

Shitara (41), 2008

Kim (36), 2008

a

Ibrahim (18), 2008

Gusani (35), 2008

Aliberti (34), 2008

Herber (27), 2007

Burger (23), 2005

Author, year

54%

disease: 51%; extrahepatic metastasis:

NR

ethiodol, polyvinyl alcohol

Male: 65%; age: 63.9/65.3; bilobar

Cisplatin, doxorubicin, mitomycin C,

NR; extrahepatic metastasis: 31%

NA

NA

Oxaliplatin then CTx

Mitomycin C

Lipiodol and cisplatin

NA

oxaliplatin

Male: 40%; age: 62; bilobar disease:

NR; extrahepatic metastasis: 31%

Male: 58%; age: 64.3; bilobar disease:

80%; extrahepatic metastasis: 49%

Male: 52%; age: 57; bilobar disease:

NR; extrahepatic metastasis: NR

Male: 65%; age: 66.5; bilobar disease:

NR; extrahepatic metastasis: 85%

Male: 59%; age: 74.5; bilobar disease:

NR; extrahepatic metastasis: 51%

Male: 76%; age: 62.9; bilobar disease:

67%; extrahepatic metastasis: 33%

Male: 67%; age: 68; bilobar disease:

gemcitabine then oxaliplatin, gemcitabine
+ cisplatin, gemcitabine + cisplatin then

Gemcitabine, gemcitabine then cisplatin,

NR; extrahepatic metastasis: NR

DC beads loaded with doxorubicin

Lipiodol (10mL) and mitomycin (10 mL)

Variable

Regime

TACE

Male: 50%; age: 58.8; bilobar disease:

NR; extrahepatic metastasis: NR

Male: NR; age: 68.5; bilobar disease:

60%; extrahepatic metastasis: 0%

Male: 33%; age: 63.6; bilobar disease:

24%; extrahepatic metastasis: 12%

Male: 24%; age: 56; bilobar disease:

Demographics

Table 2 Summary of patient characteristics

2.5

2

NA

NA

(3-7 cycles)

cycles); CTx

TACE (1-7

8

3

NA

3

3

3.9

2

procedures

No.

NA

NR

NA

NA

NR

7.8

8.9

NA

NR

6.5

10.8

NA

NA

All

All

NA

NA

NA

38

NA

NA

NA

NA

NA

85

80

NA

NA

NA

42

NA

NA

NA

NA

therapy (%)

(%)

size (cm)
NA

hepatic

session

tumor
NR

Whole

NA

NA

1.74

1.76

NA

NA

NA

NR

NA

NA

NA

NA

activity

Mean

Yttrium therapy
Single

Median
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C + gemcitabine, mitomycin C +

77%; extrahepatic metastasis: NR

Male: 52%; age: 63.3; bilobar disease:

Median

Lipiodol + mitomycin C, doxorubicin

NA

NA

3

NA

NA

2

NR

NR

NR

NR

NA

median, NR

50%;

1 session,

procedures

No.

NA

11.5

6.5-11.5

9.2

NR

NA

NA

NR

NR

NA

NA

NA

NA

79

30

NR

NA

NA

NA

NA

All

therapy (%)

(%)

size (cm)

NA

hepatic

session

tumor

NA

NR

30

NR

NA

NA

NA

NA

64

NA

Whole

NA

1.2

NR

NR

NA

1.54

NA

activity

Mean

Yttrium therapy
Single

Median

trans-arterial chemoinfusion; SIRT, selective internal radiation therapy.

a

, SIRT. CTx, systemic chemotherapy; DEBTACE, drug eluting beads TACE; N, not applicable; NR, not reported; TACE, trans-arterial chemoembolization; TACI,

metastasis: 9.6-85

bilobar disease: 24-80; extrahepatic

Male: 18-76%; age: 57-74.5;

59.5%; extrahepatic metastasis: 35%

59%; extrahepatic metastasis: NR

Range

Male: 53%; age: 64; bilobar disease:

2013

42%; extrahepatic metastasis: 58%

Male: 37%; age: 61; bilobar disease:

36%; extrahepatic metastasis: 35%

alone, cisplatin alone

doxorubicin + mitomycin, gemcitabine

NR; extrahepatic metastasis: 9.6%

Male: 54%; age: 68; bilobar disease:

Gemcitabine + cisplatin, cisplatin +

Male: 48%; age: NR; bilobar disease:

gemcitabine + cisplatin

Mitomycin C only, gemcitabine, mitomycin

NR

Total, 14; median, NR

Total, 14; median, NR

NA

Irinotecan or doxorubicin

Regime

TACE

Male: 52%; age: 60.4; bilobar disease:

NR; extrahepatic metastasis: 90%

Male: 42%; age: 63; bilobar disease:

extrahepatic metastasis: 40%

bilobar disease: NR

age: 62

Male: 80%

NR; extrahepatic metastasis: 42%

Male: 58%; age: 67; bilobar disease:

63%; extrahepatic metastasis: 24%

Male: 18%; age: 65; bilobar disease:

33%; extrahepatic metastasis: 40%

Male: 38%; age: 68; bilobar disease:

Demographics

Scheuerman (28),

a

Rafi (39), 2013

a

Mouli (26), 2013

a

Hyder (38), 2013

Vogl (30), 2012

Kuhlmann (29), 2012

Hoffman (19), 2012

a

Schiffman (40), 2011

Author, year
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Patient characteristics (Table 2)
The median age at the time of each study was between
56 and 68. The mean follow-up period was 13.7 (1.9-29)
months.
The majority of patients had bilobar disease 59.5% (2477%). Extra-hepatic metastases were present in 35% (1285%) of patients with 35% (27-100%) of patients having
received previous chemotherapy. Prior liver resection
was undertaken in 11.6% (11-40%) of patients. Postprocedure chemotherapy was administered in eight studies
(17,28,33,35,36,38,40,41).
Assessment of outcomes (Table 3)
Follow-up occurred for 13.3 [8-29] months after therapy
and radiological tumor response was recorded using
Response Evaluation Criteria In Solid Tumors (RECIST)
in all studies. The average reported RECIST value for
complete and partial response (PR) was 6% (0-35%)
and 22.4% (7-90%), respectively. The time to tumor
progression was 8.2 (1.8-10) months with a median overall
survival of 13 (9.1-30) months amongst all treatment
modalities. Median overall survival in studies using
radioembolization was 12.5 months and in studies using
chemoembolization was 13 months. Overall 1-year survival
for all treatments was 53.5 [40-78] months [median: SIRT
54.5% (40-61%), TACE 53% (38-78%)].
Treatment toxicity (Table 4)
Table 4 summarizes adverse effects associated with transarterial therapies. Side effects related to post-embolization
syndrome in several studies occurred within the first few
days of treatment (27,31,36,40). Other complications were
reported within 30 days of treatment. Delayed toxicity was
not reported. The overall rate of acute toxicity was 34.9%
(26.2-89%). Twelve studies graded the severity of toxicities
(17-19,23,27,31,32,35,38-41). Of those who experienced
treatment toxicities, 64.3% (38-79%) were considered mild
and resolved without intervention (31,35,39,40).
The most frequent clinical toxicities were abdominal
pain 40% (4-100%), nausea and vomiting 27% (6.195%), and fatigue 19% (0-75%) (17-19,26,27,34,37). The
incidence of gastroduodenal ulcers was 3% (0-20%) and
did not require invasive treatment (17,18,26,27,32,37).
Only one study by Shitara et al. reported 5% of perforated
duodenal ulcer resulting in discontinuation of therapy (41).
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Serological toxicities included hematological abnormalities
and deranged liver function test (LFT) results. Other
complications reported were hepatic abscesses, acute
myocardial infarction (AMI) and pulmonary embolism.
Importantly, there were no deaths due to treatment
toxicities.
Prognostic factors (Table 5)
Increased multiplicity, localization and vascularity of the
tumor were identified as factors associated with poor overall
survival (17,26,30,35,43). Whilst multiple and infiltrating
tumor was a negative prognostic factor for SIRT, Mouli,
2013 #114; Saxena, 2010 #35; Hoffmann, 2012 #21
hypovascularity of the tumor was associated with poor
outcome with TACE (30,43). Worse performance status
as measured by Eastern Cooperative Oncology Group
(ECOG) scale was a significant prognostic factor in studies
assessing SIRT but not in those with chemotherapy-based
treatments (17-19). Data on prognostic factors was scarce
and there was inconsistency across the studies.
Discussion
Summary of evidence and interpretation
The ideal approach to treatment of inoperable disease is
poorly defined. TAE therapies are a novel and increasingly
performed approach for treating unresectable ICC.
Outcomes are promising, but there is no standardized
protocol for treatment regime, combination of agents and
patient selection. Studies have examined clinical outcomes
of various chemotherapeutic and radioactive agents, on
their own or in combinations, but with inconsistent results
(29,30,35). Combination treatment of TACE and TACI
has also been reported (23,43). A potential alternative to
Y90 radioembolization is DEBTACE. Four studies in this
review have compared this treatment with conventional
TAE therapies (29,34,38,40).
Patient characteristics of the studies summarized in this
review confirm that trans-arterial therapies are offered to
a variety of patients with incurable disease. A significant
proportion of patients in this review had advanced disease
with bilobar tumors and extra-hepatic metastases. About
35% to 100% of patients received chemotherapy prior to
trans-arterial treatment. In 10% to 40% of patients, hepatic
resection had already been performed. The survival benefit
achieved by trans-arterial therapies across a variety of

www.thejgo.org
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TACI

TACI, TACE

Table 3 (continued)

2008

Shitara (41),

2008

Kim (36),

(18), 2008

Ibrahim

a

SIRT

DEBTACE

2008

2008

TACE +

TACE

TACE

Treatment

Aliberti (34),

2007

Herber (37),

2005

Burger (23),

Author, year
PR

SD

Response (RECIST) %
PD

27

0

90

7

5

35
45

20

(EASL) (EASL)

9

0

10

0

achieved

0

NR

68 (EASL)

57

0

70

10

NR

NR

43

0

27

resonance imaging in 44%. PR not

75% tumor necrosis on magnet

CR

Table 3 Results of included studies

8.3

10

NR

NR

NR

NR

23

14.1

12

14.9

9.1

13

21

(months)
NR

Median
(months)

free survival

Progression-

(%)

NR

NR

NR

65

100

NR

95

78

46

38

76

51

(%)

38

14

NR

27.5

30

(%)

30

4

NR

27.5

NR

(%)

NR

0

NR

NR

NR

(%)

1 year 2 years 3 years 5 years

Overall survival
months

6

months

Median survival was 14.1

The response rate was 50.0%.

55% clinical success

respectively

6.1 months, and 1 month,

1, and 2 was 31.8 months,

performance status of 0,

patients with an ECOG

The median survival for

prognostic factor for survival.

Baseline ECOG is a

months)

gemcitabine alone (6.3

(13.8 months) compared

significantly longer survival

combination TACE had

gemcitabine-cisplatin

Median survival with

patients

RECIST. Well tolerated by all

A response rate of 100% on

CCA

complications for inoperable

with a moderate number of

TACE is a safe procedure

Well-tolerated by 82%

Key points
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30

NR

(%)

months
NR

(%)
NR

(%)
NR

(%)
NR

(%)

1 year 2 years 3 years 5 years

Significantly increased overall

Key points

Saxena
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Schiffman

DEBTACE

TACE

TACE

SIRT

SIRT

Table 3 (continued)

(40), 2011

a

2011

Park (32),

2011

Kiefer (31),

2011

a

Haug (27),

(17), 2010

a

TACE

6

0

0

NR

0

6

23

7

22

26

72

67

60

65

48

17

11

27

13

22

NR

NR

NR

NR

NR

17.5

12.2

21.1

12.5

9.3

NR

76

NR

79

56

51

51

53

40

12

27.5

31

27

10

27.5

NR

13

5

NR

NR

NR

therapy to systemic CTx

therapy is used as adjunctive

survival benefit when DEB

effective, providing a marked

DEBTACE is safe and

(median 3.3 months) group

symptomatic treatment

12.2 months) than in the

in the TACE group (median

Survival period was longer

15 months

first chemoembolization was

Median survival from time of

successful radioembolisation

was not a prerequisite for

High tumour vascularization

best independent predictor.

volume at 3 months being the

metabolically active tumour

treatment, with the change in

after radioembolization

predict patient outcome

FDG PET/CT was able to

ECOG status of 0.

peripheral tumor type and

with an improved survival:

Two factors were associated

events. Decrease in tumor size

8.4

(months)

microspheres-

0

Median
(months)

free survival

survival with no major adverse

56

PD

Overall survival

eluting

44

0

SD

6

2009

PR

CR

Progression-

Oxaliplatin

Treatment

Response (RECIST) %

Poggi (33),

Author, year

Table 3 (continued)
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SIRT

TACE

SIRT

Total

Table 3 (continued)

2013

a

Mouli (26),

2013

Hyder (38),

a

2012

NR

9

61.5

57

45

10

42

52

SD

0

73 (WHO), 2 (WHO),

13

34

29

60

50

15

PD

(EASL)

9

(WHO), 64 (EASL) 0 (EASL)

2.5

NR

34.6 (EASL) 47.5 (EASL)

3.1

0

26

NR

Vogl (30),

10

NR

4

36

PR

(29), 2012

0

CR

NR

TACE

SIRT

Treatment

Response (RECIST) %

Kuhlmann

(19), 2012

Hoffman

Author, year

Table 3 (continued)

NR

NR

NR

6.2

1.8

3.9

therapy

10.9

Bilobar:

6.1

surgical resection for curative

Solitary tumor is a prognostic

types of trans-arterial therapy

Similar results across different

noted

chemotherapy protocols was

treated with different

difference between patients

No statistically significant

to cTACE

and gemcitabine, but superior

systemic ChT with oxaliplatin

control, PFS and OS similar to

PFS and OS. Local tumor

results in a prolongation of

normal liver function, and

TACE is safe in patients with

demonstrating that DEBTACE-

This is the first study

RECIST response

status, tumor burden and

survival are performance

Predictors for prolonged

Infiltrative:

16

8

0

Key points

5.7

22

10

12

(%)

allowing conversion to

NR

29

41

(%)

factor with tumor reduction

54

52

61

(%)

Multifocal:

NR

NR

NR

NR

NR

83

(%)

(%)

1 year 2 years 3 years 5 years

Overall survival
months

6

14.6

Overall:

13.4

11.6

13.2

13

11.0

5.7

11.7

22

(months)
9.8

Median
(months)

free survival

Progression-
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0

SIRT

25.5

20

22.4

NR

11

PR

3.1-35 6-44

10

TACE/TACI

All

6

NR

0

CR

All

TACE

Treatment

10-72

66.5

57

60

NR

68

SD

15

15

19.5

NR

21

PD

5-43

Response (RECIST) %

1.8-9.8

9.8

8

8.15

NR

5.7-30

12.5

13

13

11

11.5

(months)
NR

Median
(months)

free survival

Progression-

64

67

(%)

38-78

54.5

53

53.5

42

56

(%)

26

10

(%)

15

0

(%)

8

0

(%)

1 year 2 years 3 years 5 years

Overall survival
months

6

TACE

positive resection margin over

node positive patients or

benefit of surgery in lymph

There is no significant survival

No deaths within 30 days

Key points

trans-arterial chemoinfusion; SIRT, selective internal radiation therapy; SR, stable response; WHO, World Health Organization Tumor Response Criteria.

Response Criteria; NR, not reported; PR, partial response; RECIST, Response Evaluation Criteria In Solid Tumors; TACE, trans-arterial chemoembolization; TACI,

a

, SIRT. CR, complete response; CTx, systemic chemotherapy; DEBTACE, drug eluting beads TACE; EASL, European Association for the Study of Liver Tumor

Range

Median

(28), 2013

Scheuerman

2013

a

Rafi (39),

Author, year

Table 3 (continued)
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TACE

TACE +
DEBTACE

TACE

SIRT

OEM-TACE

Herber (37),
2007

Aliberti (34),
2008

Gusani (35),
2008

Ibrahim
(18), 2008

Kim (36),
2008

SIRT

www.thejgo.org

SIRT

TACE

TACE

Haug (27),
2011

Kiefer (31),
2011

Park (32),
2011

Table 4 (continued)

a

a

NR

10

NR

<30

<30

<30

<30

<30

1

2

<30

NR

65

NR

NR

NR

NR

NR

NR

NR

NR

40

17

NR

NR

NR

64

0

NR

NR

75

NR

0

NR

NR

4

NR

58

40

42

NR

NR

38

NR

100

40

6

1

NR

Nausea
50;
vomiting
19

Nausea
16,
vomiting 8

30

NR

NR

17

NR

95

27

NR

Acuity
Abdominal Nausea/
(days) Overall Fatigue
pain
vomiting

Oxaliplatin
<30
eluting
microspheresTACE

Saxena
(17), 2010

Poggi (33),
2009

Shitara (41),
2008

TACI

TACE

Burger (23),
2005

a

Treatment

Author, year

Table 4 Summary of toxicity after trans-arterial therapies

13

NR

0

0

0

Neutropenia 4

NR

NR

Thrombocytopenia 5

0

NR

NR

Haematological

13

NR

8

4

0

20;
perforated
5

NR

4

NR

0

7

NR

GIT ulcers

Toxicity (%)

AST 2.3; ALT
1.1; ALP 2.3;
bilirubin 11.2;
hypoalbuminemia
5.7

NR

0

Albumin 8,
bilirubin 4

30

NR

Bilirubin (grade 3)
4; albumin (grade
3) 71

Bilirubin 5

NR

Deranged LFTs

NR

Post-embolization
syndrome 65

NR

Alkaline toxicity 4;
anorexia 16; ascites
16; pleural effusion 8;
pulmonary embolism 4

Peripheral neuropathy
4; cholangitis 1.5;
hypertensive crisis
1.5

Gastritis 6,
cholangitis 6

Most had postembolization
syndrome which
resolved

NR

AMI 2; hepatic
abscess 2

Neoplastic fever 100;
hepatic abscess 3

Hepatic arteries
spasm 13;
anaphylactic shock 7

NR

Other

Severity

NR

65

NR

NR

NR

NR

NR

NR

38

NR

NR

NR

37

3%
APE

0

4

NR

6

NR

4

17

NR

NR

6

Grade Grade
1-2 3-4
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NR
NR

NR

SIRT

TACE +
DEBTACE

TACE

CTx

Hoffman
(19), 2012

Kuhlmann
(29), 2012
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Various

Hyder (38),
2013

SIRT

www.thejgo.org

SIRT

TACE

Rafi (39),
2013

Scheuerman
(28), 2013

NR

NR

NR

NR

NR

19

NR

21

54

17

NR

NR

10

NR

NR

NR

26.2-89 0-75

34.9

NR

89

NR

29.8

NR

NR

NR

NR

NR

26.2

4-100

40

NR

32

28

12.1

NR

NR

50

69

85

NR

6.1-95

27

NR

0

Nausea
13;
vomiting 9

6.1

NR

NR

30

0

Nausea
61;
vomiting
27

NR

0-13

4

NR

5

NR

0

NR

Febrile neutropenia 6

0

0

0

NR

Haematological

0-20

3

NR

0

2

0

NR

NR

0

0

0

NR

GIT ulcers

Toxicity (%)

2-10

Liver failure 4

Liver failure 2

32

Albumin (grade 3)
9; bilirubin (grade
3) 7

Jaundice 2;
hepatorenal
syndrome 8

NR

NR

Liver failure 10

NR

Bilirubin 70; AST
55; ALT 33

Hepatorenal
syndrome 4

Deranged LFTs

-

-

Septic shock 2;
multiple organ failure
4; AMI 11

21

Ascites 15; pleural
effusion 4

NR

NR

Death 10; peripheral
neuropathy 19

Hypertension
20; urticaria 10;
pulmonary embolism
10; cholangitis 10

Hepatic abscess 4;
pleural empyema 4

NR

Post-embolization
syndrome 27;
pneumonia 4; atrial
fibrillation 8

Other

Severity

8.5

NR

11

NR

16

NR

NR

NR

NR

0

38-79 0-37

64.3

NR

79

NR

NR

NR

NR

NR

NR

NR

63.6 36.3

Grade Grade
1-2 3-4

a

, SIRT. AMI, acute myocardial infarction; APE, acute pulmonary edema; CTx, systemic chemotherapy; DEBTACE, drug eluting beads TACE; LFT, liver function test;
NA, not applicable; NR, not reported; TACE, trans-arterial chemoembolization; TACI, trans-arterial chemoinfusion; SIRT, selective internal radiation therapy.

Range

Median

a

a

Mouli (26),
2013

a

TACE

Vogl (30),
2012

NR

1-3

TACE

a

Schiffman
(40), 2011

Acuity
(days) Overall Fatigue Abdominal Nausea/
pain
vomiting

Treatment

Author, year
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Table 5 Clinical and pathological factors associated with poorer overall survival on univariate analysis
Association with poorer overall survival

Factors

Significant

Tumor type (infiltrating vs. peripheral)

a

ECOG

a

a

Mouli (26), Saxena (17), Gusani (35): 3 studies
a

Hoffman (19) (0 vs. 1,2), Saxena (17) (0 vs. ≥1),

Non-significant
Vogl (30), Kim (36): 2 studies
Park (32): 1 study

a

Ibrahim (0 vs. 1,2) (18): 3 studies

Number of lesions (multifocal)

a

Mouli (26): 1 study

Vogl (30): 1 study

Location of lesions

Park (32), Kim (36)

Tumor burden

a

Park (32): 1 study

Tumor hypovascularity

Kim (36), Vogl (30): 2 studies

Park (32): 1 study

Extra-hepatic disease

Park (32): 1 study

Kiefer (31): 1 study

RECIST

a

Hoffman (19): 1 study

Hoffman (19) (partial response P<0.001), Gusani (35),

Park (32), Vogl (stable disease P<0.001) (30): 4 studies
TACE regime

Gusani (35) [gemcitabine-cisplatin vs. gemcitabine

Vogl (30): 1 study

alone (13.8 vs. 6.3 months, P=0.0005]: 1 study
Treatment regimes
TACE vs. TACI vs. TACE + TACI

Kim (TACI alone P<0.001) (36): 1 study

TACE + DEBTACE vs. TACE or

Kuhlmann (29): 1 study

systemic chemotherapy
Child pugh class (B vs. A)

Vogl (Child Pugh B) (30): 1 study

Kim (36): 1 study

Previous chemotherapy

a

Previous surgery

a

Portal vein thrombosis
a

Hoffman (19): 1 study
Hoffman (19): 1 study

a

Ibrahim (18): 1 study

, SIRT. AMI, acute myocardial infarction; APE, acute pulmonary edema; CTx, systemic chemotherapy; ECOG, Eastern

Cooperative Oncology Group Performance Status; DEBTACE, irinotecan drug eluting beads; LFT, liver function test; NA, not
applicable; NR, not reported; SIRT, selective internal radiation therapy; TACE, trans-arterial chemoembolization; TACI, transarterial chemoinfusion.

patient groups shows these treatments are highly effective.
However, the inconsistencies in patient demographics
reflect the lack of specific patient selection criteria for transarterial therapies and results should be interpreted in the
context of this potential bias.
Our review showed that TACE, TACI and SIRT
achieved similar rates of tumor response in unresectable
ICC (Table 3). Seven studies used radioembolization (1719,26,27,38,39). Although none of these studies reported
complete tumor response, rates for partial and stable
response (SR) were higher than the average value reported
by studies using chemoembolization. Overall and 1-year
survival rates were also similar between the chemotherapybased and radiotherapy-based approaches. Median overall
survival was 13 months. This is higher than median overall
survival of 11 months for systemic chemotherapy, reported

© Journal of Gastrointestinal Oncology. All rights reserved.

in the recent metaanalysis (11). In two studies, tumor
reduction following trans-arterial therapy allowed surgical
resection of the tumor (23,40). Surgical resection following
trans-arterial therapy allows the possibility of cure for
previously unresectable ICC.
With advances in treatment techniques and clinical
outcome, recent focus has shifted to maximizing clinical
efficacy by using combination of trans-arterial approaches,
drugs and radioactive agents. Combination of various
chemoinfusion and TACE protocols was applied upon
case-by-case assessments by Burger et al., who reported the
highest overall survival of 30 months (23). However, their
study was limited by a small sample size and absence of
control groups. Another study by Kim et al. supports that
combination therapy may enhance efficacy of TACI (36).
Whilst TACI alone was a significant negative prognostic

www.thejgo.org
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factor for overall survival, concomitant TACI and TACE
achieved similar clinical success toTACE alone (36).
Kuhlmann et al. compared systemic chemotherapy, TACE
and DEBTACE, and found that combination therapy with
TACE and DEBTACE is superior to both TACE and
systemic chemotherapy alone (29).
Chemotherapy agents used across 13 studies using
TACE and/or TACI varied widely; drugs included
cisplatin, doxorubicin, gemcitabine, 5-fluorouracil,
irinotecan, mitomycin C and oxaliplatin. Results on the
optimal drug combination are controversial. Gusani et al.
stated combination therapy using gemcitabine/cisplatin/
oxaliplatin were most beneficial for overall survival (35),
but another study found no significant differences among
drug combinations (30). Overall survival of 23 and 21 months
were demonstrated in studies using oxaliplatin (33) and
mitomycin (37), respectively. However, a quantitative
analysis is needed to assess its significance.
There are many studies analyzing predictors of survival
in resectable ICC (44,45), but data is limited on transarterial treatment of inoperable disease. Identifying
prognostic factors can optimize patient selection and
improve treatment outcomes. Currently, patient selection
criteria for trans-arterial therapies are unclear (17,36).
Prognostic factors differed between chemo- and radioembolization. ECOG status prior to treatment (17,19),
multiple or bilobar tumors (26) and greater tumor burden/
volume (19) were negatively associated with SIRT outcomes
whereas hypovascularity of the tumor (30,36) and extrahepatic involvements (32) were predictors of poor prognosis
with TACE. Poor Child Pugh Class at treatment was also
associated with poorer outcomes after TACE (30). These
observations may be related to the rationale behind the
different trans-arterial approaches. TACE exploits the fact
that tumor draws most of its blood supply from the hepatic
artery; hypervascular tumor may allow greater drug delivery
and hence higher drug concentration (5). However, in light
of the overall benefits of TAE and inadequate evidence,
patients with hypovascular tumour should not be denied
therapy until more evidence is acquired (36). SIRT delivers
radioactive particles selectively and deeply within the
tumor bed, hence greater tumor volume and multiplicity
may require higher radiation doses and wider range of
exposure risking unwanted toxicity (5). Assessment of tumor
vascularity in TACE and measurement of tumor burden
may identify ideal treatment options for patients with
unresectable ICC.
TAE is safe with mild to moderate toxicity. Overall

© Journal of Gastrointestinal Oncology. All rights reserved.
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30-day mortality in this study was 0.6% which is consistent
with t h e m o s t r e c e n t r a t e o f 0 . 7 % r e p o r t e d i n a
meta-analysis (16). Studies in our review reported acute
toxicity rate of 34.9%. The majority of post-procedural
complications was within 30 days and resolved without
intervention. The most common types of adverse effects
in both chemo- and radio-embolization were abdominal
pain, nausea and vomiting and fatigue. Mild to moderate
gastrointestinal ulcers and derangements in liver
function were also relatively common. Haematological
complications were more prevalent following TACE and
systemic chemotherapy (CTx). Hepatic abscesses were also
only observed in patients undergoing TACE (34,35,46).
This may be confounded by the higher prevalence of
hematological toxicities including neutropenia. Although
the trans-arterial approach allows more targeted delivery
of drugs and radiation without unwanted toxic exposure, a
degree of systemic toxicity may be inevitable. Nonetheless,
delayed toxicity was not recorded in any of the studies
and acute complications were mostly mild and resolved
spontaneously. The reporting of adverse events was
inconsistent between studies and not all studies graded
treatment toxicity. There was also discrepancy in the acuity
of complications. A standardized approach to assessment
of adverse outcomes may be useful to allow more accurate
comparisons of safety data.
Despite the growing evidence on the therapeutic
potential of TAE, there is only one systematic review to date
evaluating the safety and efficacy of only chemotherapybased treatments (16). However, in that study, no
limitations in study design or publication dates were applied
in their search, and the final selection of studies included
abstracts for meetings and conferences. Although our study
does not include a metaanalysis, we opted for meticulous
selection of eligible studies using specific search criteria. In
addition, meta-analysis of inappropriate and significantly
heterogeneous data is not a necessary part of systematic
reviews and the results of any metananalysis of such data
should be interpreted with caution (47). To our knowledge,
this is also the first review to assess all modalities of transarterial therapy including radioembolization.
Review limitations
The main limitation of this study was that meta-analysis
could not be performed due to statistical, methodological
and clinical heterogeneity. In particular, the heterogeneity
of patient demographics, tumor pathology and treatment
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modality resulted in significant variation in results. Much of
this is due to the lack of standardized treatment protocols.
However, this review summarizes the best available evidence
and provides useful information on the efficacy and safety of
trans-arterial therapies for unresectable ICC.

2.

3.

Guidelines for future studies
This review demonstrates the lack of appropriate and
consistent data required for meta-analysis. Prospective studies
with pre-determined and standardized data assessment will
be needed. This will facilitate consistent patient selection
criteria and outcome measures providing appropriate volume
and quality of data to accurately assess patient and disease
characteristics and treatment outcomes including safety
profile. There was no randomized controlled trial on transarterial therapies identified by our search. Future randomized
studies are required to assess efficacy of combined transarterial therapies and the use of adjuvant systemic therapies
in trans-arterial therapies. Specific drug combinations and
therapy protocols need to be investigated further to assess
the ideal treatment option for patients.
Conclusions
Trans-arterial therapies are safe and effective treatment
options for unresectable ICC. They confer improvement
in overall survival and achieve tumor reduction, allowing
curative surgical resection in some cases. Although no specific
patient selection criteria or prognostic factors for treatment
success exists, the results of this review suggest that there are
various patient and disease factors associated with clinical
outcome. In the absence of large randomised controlled
trials, these findings must be considered in conjunction with
clinical decision making tailored to each patient.
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